IMPROVED THYROID-STIMULATING HORMONE RECEPTOR POLYPEPTIDE AGONIST GLYCOFORMS TO TREAT METABOLIC SYNDROME

摘要

TSHR agonists that are substantially desialylated are described for treating metabolic syndrome and obesity and for inducing lipolysis. The TSHR polypeptide agonists are useful for treatment of hallmarks of metabolic syndrome: obesity, insulin resistance, hyperlipidemia, and liver steatosis, without producing a hyperthyroid state in treated individuals.